Prostaglandin E1 versus phentolamine/papaverine for the treatment of erectile impotence: a double-blind comparison

The use of intracavernous prostaglandin E1 was studied in 48 organically impotent men. Eight men with previous chemical priapism did not have chemically induced priapism at up to 4 times the minimum effective dose of prostaglandin E1. Of 15 men with arteriogenic impotence who had failed prior intrac...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of urology Vol. 141; no. 3; p. 549
Main Authors Lee, L M, Stevenson, R W, Szasz, G
Format Journal Article
LanguageEnglish
Published United States 01.03.1989
Subjects
Alprostadil - administration & dosage
Alprostadil - therapeutic use
Double-Blind Method
Drug Therapy, Combination
Erectile Dysfunction - drug therapy
Humans
Male
Papaverine - administration & dosage
Papaverine - therapeutic use
Penile Erection - drug effects
Phentolamine - administration & dosage
Phentolamine - therapeutic use
Online AccessGet more information

Cover

More Information
Summary:The use of intracavernous prostaglandin E1 was studied in 48 organically impotent men. Eight men with previous chemical priapism did not have chemically induced priapism at up to 4 times the minimum effective dose of prostaglandin E1. Of 15 men with arteriogenic impotence who had failed prior intracavernous phentolamine and papaverine therapy 10 had adequate erections with prostaglandin E1. A total of 25 men received intracavernous prostaglandin E1 and phentolamine plus papaverine in a double-blind fashion. Erections with prostaglandin E1 were equal or superior to those with phentolamine plus papaverine in each case.
ISSN:0022-5347
DOI:10.1016/S0022-5347(17)40889-5